Keyphrases
Placebo-controlled
100%
Phase II Trial
100%
Randomized Double-blind
100%
Pulmonary Arterial Hypertension
100%
Placebo Groups
37%
Twice Daily
37%
Background Therapy
37%
Placebo
25%
Treatment Group
25%
Intention-to-treat
25%
Least Mean Square
25%
WHO Functional Class
25%
Efficacy Endpoint
12%
Growth Hormone Receptor
12%
High-level Representation
12%
Receptor-interacting Protein Kinase 1 (RIPK1)
12%
Cough
12%
EudraCT
12%
Change from Baseline
12%
Treatment-related Adverse Events
12%
Safety Analysis
12%
Mast Cells
12%
6-minute Walk Distance (6MWD)
12%
Kinase Inhibitor
12%
Pulmonary Vascular Remodeling
12%
Pulmonary Vascular Resistance
12%
Platelet-derived Growth Factor Receptor (PDGFR)
12%
Placebo-controlled Study
12%
Stem Cell Factor
12%
Dry Powder Inhaler
12%
CSF1R
12%
Patient Intentions
12%
Interactive Response
12%
Response Technology
12%
WHO Group
12%
Community Site
12%
Gossamer
12%
Class II Patients
12%
Medicine and Dentistry
Placebo
100%
Pulmonary Hypertension
100%
Intention-to-Treat Analysis
25%
Group Therapy
25%
Least Square Analysis
25%
Receptor
12%
Adverse Event
12%
Stem Cell
12%
Cell Growth
12%
Placebo-Controlled Study
12%
Coughing
12%
Mast Cell
12%
Lung Vascular Resistance
12%
Vascular Remodeling
12%
Growth Factor Receptor
12%
Phosphotransferase Inhibitor
12%
Kinase
12%
Colony Stimulating Factor 1
12%
Colony Stimulating Factor Receptor
12%
Dry Powder Inhaler
12%
Platelet Derived Growth Factor Receptor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Pulmonary Hypertension
100%
Receptor
12%
Adverse Event
12%
Placebo-Controlled Study
12%
Coughing
12%
Growth Factor Receptor
12%
Phosphotransferase Inhibitor
12%
Colony Stimulating Factor 1
12%
Platelet Derived Growth Factor Receptor
12%
Dry Powder Inhaler
12%
Colony Stimulating Factor Receptor
12%
Vascular Remodeling
12%